The legal landscape seems to be shifting, from traditional toxic torts to a new species of such claims. Plaintiffs used to target chemical manufacturers, mainly arguing that their products polluted a water supply or the air causing injuries to local residents. Plaintiffs have not necessarily switched their focus but are now asserting toxic tort claims against companies that manufacture consumer products, suppliers of chemicals, and even manufacturing plants. Accordingly, there are important implications for product manufacturers across the spectrum. This article examines how the toxic tort landscape is changing.
This article (1) provides a brief overview of traditional toxic torts; (2) discusses three “legacy” toxic torts, asbestos, talcum powder, and benzene; (3) discusses three emerging, toxic torts, PFAS, ethylene oxide, and automotive gasoline, for which—despite an absence of reliable scientific evidence of causation—there will likely be increased litigation; and (4) offers recommendations on risk mitigation strategies for companies who are potential targets for such litigation.
The past several years have seen an increase in litigation overall and in toxic tort litigation, attributable in part to more attorney advertising and litigation funding. In fact, the American Tort Reform Association determined attorney advertising increased nearly 40% between 2020 and 2024, stating “more than $2.5 billion were spent on more than 26.9 million ads across all analyzed mediums for legal services or soliciting legal claims” across the U.S.—more than double the amount spent on pizza advertisements, at $1.1 billion during that same time. (See American Tort Reform Association, “Legal Services Advertising in the United States 2020-2024,” March 2025 edition available at "Legal Services Advertising in the United States – 2020-2024".) Historical data indicates litigation of toxic tort cases could increase if the economy struggles due to the countercyclical nature between litigation and the economy, underscoring the importance of risk mitigation and litigation preparedness for at-risk companies. (See Michael McDonald, PhD, “Finance And Law: Recessions And Lawsuits,” Above the Law, July 26, 2016, available at "Finance And Law: Recessions And Lawsuits".) There is no certainty that this will occur over the next few years if the economy trends down, but it has in the past, and there is no reason for product manufacturers to refrain from taking appropriate protective measures or to hesitate on insisting on rigorous scientific evidence during litigation. (See Eric Hudson, “The Perils of Moline, Part II – Persistence Prevails in Re-Identifying Plaintiffs in Cosmetic Talc Article,” available at "The Perils of Moline, Part II – Persistence Prevails in Re-Identifying Plaintiffs in Cosmetic Talc Article"; Pecos River Talc LLC v. Emory, Action No. 4:24cv75, 2025 U.S. Dist. LEXIS 129703, at *17 (E.D. Va. July 8, 2025) (ordering defendant in trade libel action to disclose names of research subjects because the plaintiff “[was] entitled to the names to independently determine whether defendants acted with actual malice, including by ‘purposeful[ly] avoid[ing] the truth’” where plaintiff claimed subjects’ only exposure to asbestos was through use of talc when plaintiff expert deliberately falsified such evidence in other litigation).)
Overview Of Toxic Torts
Although there is considerable overlap between traditional product liability and toxic tort cases, there are also noteworthy differences in terms of the allegations, causes of action, remedies, and defenses. Toxic tort cases often include the following characteristics that render them unique:
- Latency: Extended time period between exposure and onset of illness or alleged injury
- Scientific evidence: Plaintiffs’ reliance on questionable and minority-view scientific evidence
- Unique theories of liability: nuisance, RICO, trespass, successor liability, assault and battery
- Specific legislation: citizen suits under the Clean Water Act, the Clean Air Act, the Resource Conservation and Recovery Act (“RCRA”), the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), the Safe Drinking Water Act, the Toxic Substances Control Act, and the Emergency Planning and Community Right-to-Know Act of 1986 (“EPCRA”)
- Defendants: Involvement of many possible defendant manufacturers and/or municipalities
- Speculative damages: “no injury” recovery, medical monitoring, fear of increased risk of illness or disease
There are several different species of toxic tort claims. For instance, toxic tort claims involving consumer products are substantially similar to consumer deceptive trade practices actions, in which plaintiffs allege a manufacturer’s product contains a harmful chemical. Plaintiffs bring claims focusing on the manufacturer’s representations about the product, including claims for false or deceptive advertising, unfair trade practices, breach of express and implied warranty and fraud and misrepresentation. They typically allege economic loss claims—arguing they would not have purchased the product or would have paid less due to the claimed contamination—seeking available statutory relief and penalties, injunctive relief, and in some situations, medical monitoring for a purported increased risk of developing a disease or medical condition. Many, if not most of these cases are brought as class actions and therefore, do not allege individualized claims for relief.
Another type of toxic tort action hinges on exposure to an allegedly toxic or harmful substance, such as asbestos, in which a plaintiff or putative class of plaintiffs claim the defendant manufacturer failed to warn about the substance’s potential latent risks.
There are also actions by municipalities and state Attorneys General, seeking damages for liability based on community exposure for alleged contamination of local water, soil, and other environmental damage.
Defendants in toxic tort actions have prevailed on grounds of lack of Article III standing, lack of exposure, failure to plausibly allege that the products contained the purportedly harmful chemical or substance, lack of any representation by the manufacturer, and/or the absence of any false representations as to the characteristics or risks of the product at issue, and failure to establish medical causation. The defenses and thrust of any motions to dismiss or other dispositive motions will necessarily depend on the type of claims asserted. In addition, plaintiffs in several toxic tort actions have sought to demonstrate the presence of purported pollutants or toxins through questionable “independent” laboratory testing, which although is weak science, is a vulnerable area on which corporate defendants must focus in defending against such claims—and notably resulted in disqualification of a plaintiffs’ side expert for deliberately falsifying evidence of alternative asbestos exposure in the talc litigation. (Hudson, Ibid. at 2.)
Traditional Toxic Torts
Asbestos Litigation
The Product and the Problem: Asbestos, widely considered the “grandfather” of all toxic torts, was widely used in manufacturing because of its beneficial properties, including the ability to weather “forces of fire and corrosion,” and the versatility to be utilized in textiles, brake systems, shipyards, and engines. (See August 30, 2022, In Re: Asbestos Prod. Liab. Litig. Case No. 2:01-md-00875-ER, (E.D. Pa. July 29, 1991) (“MDL 875) Termination Order at 1.) When its fibers become damaged or “friable” and float through the air in large quantities, asbestos becomes harmful and can damage the lungs, but such injuries may not become apparent for years or even decades. That latency explains why the litigation continues despite knowledge of the dangerous characteristics of asbestos. (Id. at 2.) The most common injuries associated with asbestos include mesothelioma, lung and gastrointestinal cancer, and asbestosis. (A Guide to Toxic Torts, 3 Toxic Torts Guide § 21.01, Matthew Bender (2024).)
The Legal Landscape: The asbestos litigation, which commenced in the early 1900s but became widespread in the 1970s, as plaintiffs filed suit against hundreds of manufacturers of asbestos-containing products, is widely attributed as the longest running mass tort litigation. (Id.) The Asbestos MDL No. 875, centralized in the Eastern District of Pennsylvania in 1991 was finally terminated in 2022 [See United States Judicial Panel on Multidistrict Litigation, MDL Statistics Report, Multidistrict Litigations Terminated Through September 30, 2023, available via the PDF], but litigation persists today due to the long latency time between exposure to an asbestos-containing product and the development of alleged injuries. (See Christie J. Nicholson, “A Brief History of Asbestos Litigation,” FindLaw, January 16, 2024.) The prevalence of litigation propelled many states to enact asbestos-specific legislation requiring plaintiffs to demonstrate certain criteria to make a prima facie case for asbestos exposure. (See, e.g., Ga. Code Ann. §§ 51-14-1 to 51-14-1-10; Iowa Code § 686B.3 et seq.; Kan. Stat. §§ 60-4901-4911; Ohio Rev. Code § 2307.92; Tex. Civ. Prac. & Rem. Code § 16.0031.) Thousands of asbestos cases continue to be filed every year, and historically recessions or other periods of economic turmoil have resulted in an increase in such filings.
Despite the passage of time, asbestos litigation still remains. This is borne out by the increase in asbestos filings from 2022-2024, with nearly 4000 filings last year. (See KCIC Industry Report, “Asbestos Litigation: 2024 Year in Review,” 2024.
Talcum Powder Litigation
The Product(s) and the Problem: In the talcum powder litigation, plaintiffs alleged they were exposed to asbestos in baby powder and other talc-containing products—despite the increasingly apparent unethical conduct by a leading plaintiffs’ expert—that led to her disqualification for one case and increased scrutiny and even counter suits for falsifying evidence. (Hudson, Ibid. at 2.) Like asbestos, talc is a naturally occurring mineral, and has wide-ranging uses, including cosmetics and other personal care products, such as absorbing moisture, minimizing taking, and smoothing the appearance of skin. (“Talcum Powder and Cancer,” American Cancer Society.)
The Legal Landscape: Currently the majority of talc-related cases are in In Re: Johnson & Johnson Talcum Powder Products Mktg., SalesPrac., and Products Liab. Litig. MDL No. 2738, opened in 2016, currently the largest MDL by far, with nearly 68,000 actions pending as of August 1, 2025. (See United States Judicial Panel on Multidistrict Litigation. (2025, August 1). MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending.) (“Talcum Powder MDL”).) The Talcum Powder MDL plaintiffs, and claimants in other litigation allege that the use of talcum powder contaminated with asbestos has caused or increased the risk of cancer, with a particular focus on ovarian and lung cancer. Plaintiffs have received several “nuclear” verdicts in California and Missouri involving talcum powder-containing products over the last several years, including one punitive damages award surpassing $2 billion dollars. (See Cara Salvatore, “Mo. High Court Won't Review $2.1B J&J Talc Verdict,” November 3, 2020, Law360, Marathon Strategies, “Corporate Verdicts Go Thermonuclear: Large Jury Awards Rise Nearly 30%,” 2024 Edition.) These verdicts remain on appeal. Conversely, several leading plaintiff-side experts have been sued for trade libel due to their deliberately false research, which likewise remains pending. (Hudson, Ibid. at 2; James Beck, “Stupid Expert Tricks Redux,”; Pecos River Talc LLC v. Emory, 2025 U.S. Dist. LEXIS 129703 (E.D. Va., pending).) Also in the mix are advances in genetic research that have recently produced significant evidence that, contrary to long-standing plaintiffs’ claims, inherited genetic mutations cause mesothelioma independently of any asbestos exposure. (E.g., David Schwartz & Kirk Hartley, “What Gene Findings Mean For Asbestos Mesothelioma Claims,” Law 360 (May 29, 2025.)
Manufacturers must be prepared for the nuances of the talcum powder cases—and other toxic torts—in which plaintiffs who have no current physical injury—seek damages for future injuries or for purely economic harm. The “increased risk” and “fear of” claims are particularly concerning, because they rely on allegations that a product allegedly contained a contaminant and, therefore subjected the plaintiff to an unquantifiable and unrealized risk of cancer or another disease, resulting in considerable damages that may be amplified in class or multi-plaintiff lawsuits. The plaintiffs’ bar suffered a significant setback through the revelation of their expert’s falsification of exposure evidence by claiming that the 33 subjects of a study were exposed to asbestos only through talcum powder despite clearly documented alternative sources of exposure, and similar conduct may have occurred in other talc litigation. (Hudson, Ibid. at 2. See generally Pecos River Talc LLC v. Emory, 2025 U.S. Dist. LEXIS 129703.)
Benzene Litigation
The Product and the Problem: Another “legacy” toxic tort is the benzene litigation. In March 2024, Valisure Labs filed a Citizen Petition with the FDA, claiming certain over-the-counter acne medications were contaminated with a carcinogen, benzene. (See March 5, 2024, Valisure Citizen Petition on Benzene in Benzoyl Peroxide Drug Products.) Valisure claimed it tested products for benzoyl peroxide (“BPO”), which the lab asserted metabolizes into benzene, arguing there were “serious concern over the safety of drug products formulated with BPO,” and requesting FDA “recall and suspend sales of” BPO products.” (Id. at 1.) Plaintiffs allege benzene exposure through inhalation, ingestion, or skin absorption causes leukemia, blood disorders, heart and kidney disorders and other physical and mental disorders. (Id.)
The Legal Landscape: Although Valisure’s testing methodology is highly questionable, based on its spot testing of products at unrealistic temperatures and other unvalidated conditions, its Petition created publicity, but FDA issued a statement noting out of 95 products, “more than 90% of tested products had undetectable or extremely low levels of benzene.” (See March 11, 2025, FDA Statement, “Limited number of voluntary recalls initiated after FDA testing of acne products for benzene; findings show a small number of products with elevated levels of benzene contamination.”) The JPML denied plaintiffs’ motion to centralize a benzoyl peroxide MDL, finding there were too many defendants, and many products that varied “with respect to their formulations, the quantity of benzoyl peroxide they contain, how the products are packaged and stored, and how they are labeled and marketed.” (August 1, 2024, JPML Order Denying Transfer In Re: Benzoyl Peroxide Marketing, Sales Practices And Products Liability Litigation, MDL No. 3120 at 2.) However, the Panel determined that the creation of “defendant-specific hubs” might more effectively facilitate resolution of the benzene litigation, and as a result, there are roughly 35 putative class actions throughout 10 district courts in California, Hawaii, Illinois, Louisiana, Minnesota, New York and South Carolina. (Id. at 3.)
Emerging Toxic Torts
PFAS Litigation
The Product(s) and the Problem: One of the fastest growing toxic torts, because of the ubiquitous presence of this class of chemicals, significant number of compounds—(numbering more than 15,000 synthetic chemicals resistant to heat, grease, oil and water)—and extremely long decomposition time, is the litigation involving Per– and Polyfluoroalkyl Substances (“PFAS”). (“Our Current Understanding of the Human Health and Environmental Risks of PFAS.”) The use of PFAS-containing products dates to the 1940s, encompasses thousands of products across many industries, including fabric, carpeting, cleaning products, paint, cookware, food processing and packaging, medical devices and many more, resulting in thousands of lawsuits across the country. (Id.) The understanding of PFAS is still in its early stages, but they break down very slowly, are found in the blood of almost all humans and animals, and there is a debate within the scientific community on whether and under what conditions exposure may result in harmful effects. (Id.) However, the presence of PFAS in a myriad of different consumer, industrial, and commercial products makes it a challenge to study the environmental and health effects and to prove causation in litigation. Thus, it is not clear how to detect PFAS, how harmful long-term exposure is, and the best manner in which to remove and dispose of PFAS.
The Legal Landscape: In January 2019, the JPML centralized and MDL in the District of South Carolina, In Re: Aqueous Film-Forming Foams Products Liability Litigation, MDL 2873, which as of August 1, 2025, included more than 16,000 actions throughout its history. (JPML MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending.) Further, although MDL 2873 is focused on fire suppression foam, the list of products containing PFAS includes thousands of products and types of chemicals, and due to their long-lasting nature, PFAS have been described as “forever chemicals,” with predictions that the litigation will eclipse asbestos in its scope. (Hiroko Tabuchi, “Lawyers to Plastics Makers: Prepare for ‘Astronomical’ PFAS Lawsuits,” N.Y. Times, (May 28, 2024).) EPA and FDA have issued regulations governing PFAS, including standards for drinking water, and limitations on PFAS in food and beverages. (See “Key EPA Actions to Address PFAS;” “Per- and Polyfluoroalkyl Substances (PFAS)”) The impact that these regulations will have on potential liability, if any, remains to be seen.
All of these factors point toward PFAS litigation being persistent and becoming more prevalent, as commentators have observed “the chemicals are so pervasive that the sprawling litigation is certain to continue and grow.” (See Brendan Pierson, “Mass Tort Litigation to Watch in 2025,” Reuters, (December 23, 2024).) In addition to the consumer products litigation seeking economic damages for false advertising, deceptive trade practices and fraud-based claims, there are already lawsuits alleging contamination of natural resources and an alleged increased risk of disease and other harms. (Tabuchi, Ibid. at 8.)
Ethylene Oxide Litigation
The Product and the Problem: Another toxic tort litigation involves ethylene oxide (“EtO”), a colorless, odorless gas used to create chemicals used in detergents or antifreeze. EtO is most commonly used as a sterilizing agent for medical devices that cannot otherwise be sterilized or would be harmed by other sterilization methods. (“Sterilization for Medical Devices.”) Thus, EtO plays an important role in allowing medical device manufacturers to ensure their products are safe. Approximately half of all medical devices, including polymers made of resin or plastic, catheters, wound dressings and stents are sterilized using EtO. (Id.) EtO is also used to sterilize certain consumer goods, including foods and spices. (See “Hazardous Air Pollutants: Ethylene Oxide (EtO), Our Current Understanding of the Human Health and Environmental Risks of Ethylene Oxide,” EPA.GOV.) Plaintiffs allege EtO is released into the air as a gas or contaminates the water and exposure purportedly causes cancer, infertility, and other adverse health conditions.
The Legal Landscape: FDA recently issued industry guidance on the use of EtO sterilization. (See FDA Guidance for Industry and Food and Drug Administration Staff, “Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices” (November 2, 2024).) The active EtO litigation includes more than 1600 cases filed since the beginning of 2023 alleging damages or injuries from the use or contamination with ethylene oxide. EPA conducted an assessment of EtO emissions in July 2022 and identified 24 facilities that purportedly posed an increased risk of cancer through contamination of local environments. (See Community Engagement on Ethylene Oxide (EtO).”) EPA also released a list of 100 sterilization facilities utilizing EtO, spanning 33 states and including many medical device and pharmaceutical manufacturers. (See “Ethylene Oxide Sterilization Facilities.”)
There have been a number of high-profile EtO cases, including an award against a medical device sterilizer for a single plaintiff in excess of $360 million, with more than $300 million in punitive damages. (See Greg Scoblete, “A Primer on Ethylene Oxide for P/C Insurers,” (January 25, 2024).) Another device sterilizer reached a $400 million settlement with 800 plaintiffs. (Id.) Other noteworthy cases include an ongoing class-action lawsuit in Tennessee state court in which plaintiffs are seeking certification of a medical monitoring subclass. (Id.; Bowden v. Sterilization Services of Tennessee (SST), Case No. CT-2768-23 (Tenn. Cir. Aug. 8, 2025).) Similarly, the FDA and EPA’s focus on EtO regulation should alert medical device manufacturers, sterilization facilities and commercial companies whose operations require EtO to continue to monitor compliance, and to implement appropriate risk mitigation and management measures.
Fuel Litigation
The Product and the Problem: Litigation over automotive gasoline merits monitoring because the World Health Organization, through the International Agency for Research on Cancer (“IARC”), recently characterized auto fuel as a carcinogen in March 2025. (See “IARC Monographs evaluation of the carcinogenicity of automotive gasoline and some oxygenated gasoline additives,” (March 21, 2025).) Specifically, the IARC analyzed auto gas and “oxygenated gasoline additives,” concluding that gasoline was a Group 1 “carcinogenic” compound, and ethyl tert-butyl ether (“MTBE”) and ethyl tert-butyl ether (“ETBE”), were Group 2B “possibly carcinogenic” compounds. (Id.) The IARC’s Working Group stated that there was “sufficient evidence for cancer in humans and the combination of sufficient evidence for cancer in experimental animals and strong mechanistic evidence in exposed humans,” and that auto fuel “causes cancer of the urinary bladder and acute myeloid leukemia in adults.” (Id.) The Working Group found a “causal association between automotive gasoline” and a variety of childhood cancers. (Id.) However, IARC’s determination is hardly conclusive, and the IARC has a history of issuing outlier evaluations about the carcinogenicity of other chemicals such as pesticides, benzene, and a variety of pharmaceutical products, (and in fact is the only agency to assert that certain pesticides can cause cancer) leading to a proliferation of litigation by plaintiffs who tout the evaluations as scientific fact.
The Legal Landscape: Although there is not yet a large volume of toxic tort litigation over the allegedly harmful effects of auto fuel, the IARC’s inclusion of this product on its cancer monograph is significant and places on notice manufacturers of fossil fuels, energy companies, and manufacturers who utilize auto fuel. Looking ahead, the increased attention on automotive fuel necessitates vigilance on the part of organizations who produce, rely on, and use fossil fuels.
Our Recommendations for Risk Reduction
Companies who believe they have potential exposure to these kinds of lawsuits should implement the following steps to mitigate the risks of litigation.
- Insurance coverage: Review insurance agreements to determine the liabilities for which there is available coverage, regarding claims, litigation, and settlements.
- Suppliers and vendors: Review agreements with third-party vendors and suppliers to ensure compliance with applicable regulations and to assess potential exposure to any potential risks or gaps.
- Regulatory compliance: Stay abreast of regulatory requirements and ascertain compliance.
- Outside counsel: Contact legal counsel for risk evaluation, and for impending litigation, and early case assessments.
Taking meaningful steps to prepare today may in some cases avert, or at least minimize, the pitfalls of tomorrow.
This article was originally published on DRI.org in the For the Defense September 2025 Edition.